Clinical Trial Update: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) [Phase 1, Phase 2]

View source ↗

Summary

Merck's IDX719, an NS5A inhibitor, was studied in healthy volunteers and patients with chronic hepatitis C in a Phase 1/2 trial (MK-1894-001), and the study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX719 (NS5A inhibitor)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 1, Phase 2 | Status: COMPLETED